<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04949997</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00006761-M2017152</org_study_id>
    <nct_id>NCT04949997</nct_id>
  </id_info>
  <brief_title>Evaluation of Systolic Function in Heart Failure With Middle Ejection Fraction by 3D Speckle Tracking Imaging</brief_title>
  <official_title>Evaluation of Left Ventricular Systolic Function in Heart Failure With Middle Ejection Fraction by 3D Speckle Tracking Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In 2016, the European Heart Association defined the median ejection fraction heart failure&#xD;
      for the first time. More research is needed to improve our understanding of this population,&#xD;
      so as to make the best clinical decision and improve the prognosis. In this study, 3D-STI was&#xD;
      used to evaluate left ventricular systolic function in heart failure with median ejection&#xD;
      fraction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As the final manifestation of cardiovascular disease and the main cause of death, heart&#xD;
      failure is one of the important challenges threatening human health in the 21st century. In&#xD;
      2016, the European Heart Association proposed a new classification standard for heart&#xD;
      failure. In particular, for the first time, heart failure with median ejection fraction has&#xD;
      been clearly defined. These patients have received more and more attention, but there are&#xD;
      still relatively few studies on them. More research is needed to improve our understanding of&#xD;
      this part of the population in order to make the best clinical decisions and improve the&#xD;
      prognosis. 3D speckle tracking technology is a new technology developed on the basis of&#xD;
      real-time three-dimensional echocardiography and speckle tracking technology. It is gradually&#xD;
      recognized in the evaluation of left ventricular systolic and diastolic function, especially&#xD;
      in the evaluation of cardiotoxicity of chemotherapy drugs. At present, the application of&#xD;
      3D-STI in the evaluation of left ventricular systolic function in heart failure with median&#xD;
      ejection fraction is limited and needs further study.In this study, 3D-STI was used to&#xD;
      evaluate left ventricular systolic function in heart failure with median ejection fraction.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Actual">May 31, 2019</completion_date>
  <primary_completion_date type="Actual">March 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>3D-STI measurement indexes</measure>
    <time_frame>one week</time_frame>
    <description>strain values of different sections from 3D-STI</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">130</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>patients without heart failure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HF</arm_group_label>
    <description>patients with heart failure</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnose</intervention_name>
    <description>HF was divided into HF with preserved ejection fraction, HF with median ejection fraction and HF with reduced ejection fraction.</description>
    <arm_group_label>HF</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients meet the diagnostic and classification criteria of heart failure proposed in the&#xD;
        2016 ESC guidelines for HF but not the exclusion criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Meeting the diagnostic and classification criteria of heart failure proposed in the 2016&#xD;
        ESC guidelines for the diagnosis and treatment of acute / chronic heart failure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. acute or chronic infectious diseases;&#xD;
&#xD;
          2. COPD, chronic bronchitis, emphysema and other serious lung diseases;&#xD;
&#xD;
          3. Autoimmune diseases;&#xD;
&#xD;
          4. Malignant tumor;&#xD;
&#xD;
          5. Acute, chronic liver disease or other reasons lead to abnormal liver function&#xD;
             (transaminase is more than 3 times of normal value);&#xD;
&#xD;
          6. Acute and chronic kidney disease, end-stage renal disease (serum creatinine &gt; 220&#xD;
             Î¼mol/L, or creatinine clearance rate &lt; 30 ml/min);&#xD;
&#xD;
          7. Heart valve disease;&#xD;
&#xD;
          8. Severe arrhythmia;&#xD;
&#xD;
          9. The image quality of echocardiography was poor when it was larger than three sections;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 29, 2021</study_first_submitted>
  <study_first_submitted_qc>June 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2021</study_first_posted>
  <last_update_submitted>June 29, 2021</last_update_submitted>
  <last_update_submitted_qc>June 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>median ejection fraction</keyword>
  <keyword>3D-STI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

